Show simple item record

dc.contributor.authorAdalsteinsson, Jonas A
dc.contributor.authorMuzumdar, Sonal
dc.contributor.authorWaldman, Reid
dc.contributor.authorHu, Chaoran
dc.contributor.authorWu, Rong
dc.contributor.authorRatner, Désirée
dc.contributor.authorUngar, Jonathan
dc.contributor.authorSilverberg, Jonathan I
dc.contributor.authorOlafsdottir, Gudridur H
dc.contributor.authorKristjansson, Arni Kjalar
dc.contributor.authorTryggvadottir, Laufey
dc.contributor.authorJonasson, Jon Gunnlaugur
dc.date.accessioned2021-04-27T11:35:44Z
dc.date.available2021-04-27T11:35:44Z
dc.date.issued2020-08-11
dc.date.submitted2021-04
dc.identifier.citationAdalsteinsson JA, Muzumdar S, Waldman R, Hu C, Wu R, Ratner D, Ungar J, Silverberg JI, Olafsdottir GH, Kristjansson AK, Tryggvadottir L, Jonasson JG. Association between hydrochlorothiazide and the risk of in situ and invasive squamous cell skin carcinoma and basal cell carcinoma: A population-based case-control study. J Am Acad Dermatol. 2021 Mar;84(3):669-675. doi: 10.1016/j.jaad.2020.08.025.en_US
dc.identifier.pmid32791082
dc.identifier.doi10.1016/j.jaad.2020.08.025
dc.identifier.urihttp://hdl.handle.net/2336/621763
dc.descriptionTo access publisher's full text version of this article click on the hyperlink belowen_US
dc.description.abstractBackground: Population-based studies analyzing hydrochlorothiazide's (HCTZ's) effect on keratinocyte carcinoma, and particularly invasive squamous cell carcinoma (SCC), are lacking. Objectives: To characterize the association between HCTZ use and invasive SCC, SCC in situ (SCCis), and basal cell carcinoma (BCC). Methods: This population-based case-control study included all 6880 patients diagnosed with first-time BCC, SCCis, and invasive SCC between 2003 and 2017 in Iceland and 69,620 population controls. Conditional logistic regression analyses were used to calculate multivariate odds ratios (ORs) for keratinocyte carcinoma associated with HCTZ use. Results: A cumulative HCTZ dose above 37,500 mg was associated with increased risk of invasive SCC (OR, 1.69; 95% confidence interval [CI], 1.04-2.74). Users of HCTZ also had an increased risk of SCCis (OR, 1.24; 95% CI, 1.01-1.52) and BCC (OR, 1.14; 95% CI, 1.02-1.29). Limitations: Limitations include this study's retrospective nature with the resulting inability to adjust for ultraviolet exposure, Fitzpatrick skin type, and comorbidities. Conclusions: High cumulative exposure to HCTZ is associated with the development of keratinocyte carcinoma and, most importantly, invasive SCC. Sun protective behaviors alone may not eliminate the carcinogenic potential of HCTZ. Keywords: basal cell carcinoma; epidemiology; hydrochlorothiazide; keratinocyte carcinoma; squamous cell carcinoma.en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.urlhttps://www.sciencedirect.com/science/article/pii/S0190962220324130?via%3Dihuben_US
dc.rightsCopyright © 2020 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.
dc.subjectbasal cell carcinomaen_US
dc.subjectepidemiologyen_US
dc.subjecthydrochlorothiazideen_US
dc.subjectkeratinocyte carcinomaen_US
dc.subjectsquamous cell carcinomaen_US
dc.subjectHúðkrabbameinen_US
dc.subjectFlöguþekjukrabbameinen_US
dc.subject.meshHydrochlorothiazideen_US
dc.subject.meshCarcinoma, Squamous Cellen_US
dc.titleAssociation between hydrochlorothiazide and the risk of in situ and invasive squamous cell skin carcinoma and basal cell carcinoma: A population-based case-control study.en_US
dc.typeArticleen_US
dc.identifier.eissn1097-6787
dc.contributor.department1Faculty of Medicine, University of Iceland, Reykjavik, Iceland; University of Connecticut Department of Dermatology, Farmington, Connecticut. Electronic address: adalsteinsson@uchc.edu. 2University of Connecticut Department of Dermatology, Farmington, Connecticut. 3Connecticut Convergence Institute for Translation in Regenerative Engineering, Farmington, Connecticut. 4New York University Langone Health, Department of Dermatology, New York, New York. 5Mount Sinai Department of Dermatology, New York, New York. 6The George Washington University School of Medicine and Health Sciences, Washington, DC. 7Icelandic Cancer Registry, Reykjavik, Iceland. 8Department of Pathology, Landspitali National-University Hospital, Reykjavik, Iceland. 9Faculty of Medicine, University of Iceland, Reykjavik, Iceland; Icelandic Cancer Registry, Reykjavik, Iceland. 10Faculty of Medicine, University of Iceland, Reykjavik, Iceland; Department of Pathology, Landspitali National-University Hospital, Reykjavik, Iceland.en_US
dc.identifier.journalJournal of the American Academy of Dermatologyen_US
dc.rights.accessNational Consortium - Landsaðganguren_US
dc.departmentcodePTT12
dc.source.journaltitleJournal of the American Academy of Dermatology
dc.source.volume84
dc.source.issue3
dc.source.beginpage669
dc.source.endpage675
dc.source.countryUnited States


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record